This site is intended for healthcare professionals

News

AveXis/Novartis receives EC approval and activates “Day One” access program for Zolgensma, the only gene therapy for spinal muscular atrophy (SMA).

Read time: 3 mins

Last updated:20th May 2020

Published:20th May 2020

Condition: Spinal Muscular Atrophy

Type: drug

Register now for full access to medthority.com

Click here to register now